Indivior reported 146M in Operating Profit for its fiscal semester ending in March of 2026.





Operating Profit Change Date
AstraZeneca USD 3.16B 3.95B Jun/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Roche Holding CHF 11.46B 1.91B Jun/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026